Home » Illumina Licenses Nanopore-based Sequencing Technology from UAB-UW

Illumina Licenses Nanopore-based Sequencing Technology from UAB-UW

Oct 15, 2013
|
a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The University of Alabama, Birmingham announced on Monday that it and the University of Washington have licensed to Illumina the rights to nanopore sequencing technology developed by a UAB microbiologist and a University of Washington physicist.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Articles

Jul 08, 2014

Following Publication, UW Team Pursues Better Accuracy for De Novo Nanopore Sequencing

Premium
Jun 24, 2014

Pre-print Study Demonstrates Nanopore Sequencing of Bacteriophage Genome with MspA Pore

Premium
Apr 08, 2014

Commercial Nanopore Sequencer Remains 'Top Goal' for Electronic BioSciences after Nanopatch Launch

Premium
Jun 02, 2014

Roche Acquires Nanopore Sequencing Firm Genia Technologies for up to $350M

Aug 22, 2014

Researchers Combine Nanopores and Optical Sensing in Single-molecule Detection Device

Premium
Jul 22, 2014

IBM Team, Still Active in Sequencing, Shows Fabrication of Nanopore Arrays with Embedded Electrodes

Premium

The Scan

This Week in Science

In Science this week: gene regulation changes linked to human brain evolution, and more.

Seven Steps

The New York Stem Cell Foundation's Initiative on Women in Science and Engineering working group presents seven strategies to promote gender equality in the sciences.

Arsenic Adaptation

Researchers link a genetic variation to the ability to quickly process arsenic in people living in the Andes Mountains.

NIPT Tests Find Cancer in Some Pregnant Women

A small portion of pregnant women who've undergone non-invasive prenatal testing have found out from the test that they have cancer.

What's Popular?

In Clinical Sequencing

  1. Patent Pool Provides Sequenom Second Revenue Stream, Frees it to Focus on New Products

    Premium

  2. In NEJM, Lander Lauds Steps at FDA to Build New Regulatory Framework for Genomic Tests

  3. N-of-One Inks Deal With NeoGenomics to Interpret Cancer Dx Tests

  4. Natera Preps Move into Cancer Dx Market as it Continues Building NIPT Capabilities

  5. Q&A: Matt Posard on Illumina's Clinically Focused Business Unit

    Premium

Sponsorships

Privacy Policy.  Copyright © 2015 Genomeweb LLC.  All Rights Reserved.